Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Press Release

Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data –   NEW YORK, November 21, 2024 – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud…

BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT

Press Release

Vancouver, British Columbia, November 4, 2024 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”)announcesthat further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of1,612,902common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Sharefor aggregate gross proceeds…